Pre-market hot trades in US stocks: Synchrony Financial pre-market down 9.38%; Allogene Therapeutics pre-market up 9.36%

Pre-market Hot Trades in US Stocks Synchrony Financial is down 9.38% in pre-market trading. Based on recent news, On January 9, Darrin Peller, an analyst at Wolfe Research, maintained a buy rating on Synchrony Financial with a target price of $98. Nevertheless, the market's reaction to this rating was limited, and the stock price failed to gain traction. On January 9, Moshe Orenbuch, an analyst at TD Cowen, also issued a buy rating on Synchrony Financial. However, Robert W. Baird maintained a hold rating on the company on January 6, indicating a divergence in market sentiment regarding the stock. On January 10, several financial institutions, including the American Bankers Association, jointly stated that they would work with the government to ensure that Americans have access to the credit they need. This statement failed to alleviate market concerns about the financial industry, leading to a decline in Synchrony Financial's stock price. The financial sector is facing policy uncertainty, and market sentiment remains cautious. ALLO is up 9.36% in pre-market trading. Based on recent key news: On January 10, Citizens Bank upgraded Allogene Therapeutics to outperform, citing its discounted earnings per share and revenue multiple analysis. Analyst Reni Benjamin noted that the main asset, cema-cel, has performed well in the allogeneic CAR T treatment for frontline large B-cell lymphoma and is expected to succeed in the Phase 2 trial of ALPHA-3. This trial is expected to conduct an efficacy assessment in the second quarter. The Phase 1 study of cema-cel showed a 58% objective response rate and a 42% complete response rate, with a median duration of response of 11.1 months. Benjamin anticipates peak sales of approximately $1 billion by 2033. Although still in Phase 1, Benjamin is excited about ALLO-329, a pioneering allogeneic CD19/CD70 dual CAR T for autoimmune diseases. Preliminary proof-of-concept data is expected to be released later in the first half of the year, and management indicated that the results will help determine future indications. The biotechnology sector has been active recently. Top Gainers in Pre-market US Stocks Ping An Biomedical is up 66.95% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Intelligent Bio Solutions is up 53.46% in pre-market trading. Based on recent key news: On January 8, Intelligent Bio Solutions released important company information through the EDGAR system, resulting in a significant increase in stock price. This information was published by the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission, enhancing market confidence in the company's future development. On January 9, analysts rated Intelligent Bio Solutions as a hold, with a target price of $11. Despite the company's weak financial performance, technical factors support a rise in stock price, which has surpassed key moving averages, driving further increases. Recently, the company's development has been mixed, with financing and expected manufacturing cost savings offset by a reverse split driven by listing compliance. Nevertheless, the stock price is still supported by technical improvements. Technical improvements support a rise in stock price, and market confidence is strengthening. Signing Day Sports rose 30.46% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation